Intracerebral Hemorrhage News and Research

RSS

Intracerebral hemorrhage (ICH) is sudden, catastrophic bleeding that occurs in the brain tissue or ventricles. It usually results from damage to blood vessels due to hypertension. Symptoms are often sudden and severe. Loss of consciousness, vomiting, and headache are all common, but milder presentations are also possible, resembling ischemic stroke.

Conflicts in medical management of hemophilia

Hemophilia is a medical disorder that is part of our genetic load as humans. It will never disappear. Therefore, the only way to live with it is to receive adequate medical management. Its effects on those males who have inherited the disorder that affects their blood clotting without treatment includes recurrent hemorrhages (bleeds) into joints as well as internal bleeding. The bleeds are painful, resulting in disuse, disability and crippling. The first signs usually appear in early childhood. A child who suffers a mouth bleed can slowly lose enough blood to result in death.

8 Mar 2011

CARBOGEN AMCIS installs new stability chambers at Switzerland facility

Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has expanded its service portfolio and capacity for stability studies. In compliance with the latest International Conference on Harmonisation (ICH) guidelines, and in response to customer demand, the company has installed new stability chambers at the Hunzenschwil (Neuland), Switzerland operations and offers short-term, long-term, accelerated, intermediate, follow-up and customized tests.

21 Feb 2011

FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.

19 Feb 2011

Study: Native Hawaiians face high risk of hemorrhagic stroke and diabetes at younger age

Native Hawaiians and Pacific Islanders may be at higher risk for hemorrhagic stroke at a younger age and more likely to have diabetes compared to other ethnicities, according to a study released today that will be presented at the American Academy of Neurology's 63rd Annual Meeting in Honolulu April 9 to April 16, 2011.

16 Feb 2011

Almac opens analytical facility at new 240,000 sq. ft. North American Headquarters

Almac's new 240,000 sq. ft. North American Headquarters, built on 40 acres in Souderton, PA, north of Philadelphia is part of the Almac Group's integrated services solutions strategy. The new facility delivers full-service, integrated clinical packaging, drug supply management and technology solutions to pharmaceutical and biotech clients.

8 Feb 2011

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2010.

8 Feb 2011

Researchers identify key player that lead to increased bleeding in diabetes patients with stroke injury

Strokes are a leading cause of mortality and adult disability. Those that involve intracerebral hemorrhage are especially deadly, and there are no effective treatments to control such bleeding. Moreover, diabetes and hyperglycemia are associated with increases in bleeding during hemorrhagic stroke and worse clinical outcomes.

24 Jan 2011

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

Sanofi-aventis, Oxford University to conduct multi-phase oncology research in India

Sanofi-aventis US and Oxford University have entered into an agreement to conduct multi-phase oncology clinical and epidemiological research with INDOX, India's leading academic oncology network.

20 Dec 2010

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.

8 Nov 2010

Pharma Lynx licenses NewCardio's QTinno automated cardiac safety solution

NewCardio, Inc., a cardiovascular diagnostic solutions developer, announced today that Pharma Lynx, a global contract research organization and a subsidiary of Diverse Lynx, has signed an MSA to license NewCardio's QTinno™ solution for use in Phase 1 studies. Pharma Lynx has particular expertise in oncology studies, including QTc studies involving both healthy subjects and cancer patients, and QTinno will add to Pharma Lynx's already robust capabilities, enabling it to deliver fully automated QTc studies to its sponsors.

17 Sep 2010

Mexican-American stroke survivors with atrial fibrillation at increased risk for second stroke

Mexican-American stroke survivors with a heart rhythm disorder have more than twice the risk for another stroke compared to non-Hispanic whites, according to a study published in Stroke: Journal of the American Heart Association.

10 Sep 2010

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada.

2 Sep 2010

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

Cetero Research, the leading early stage contract research organization (CRO), today announced the expansion of multiple Clinical Dermatology and Transdermal Delivery System (TDDS) services to four Cetero clinical facilities.

20 Aug 2010

NIEHS procures Provantis preclinical software solution for National Toxicology Program studies

Instem, a leading provider of early drug development software solutions, announced today that the National Institute of Environmental Health Sciences has purchased the Provantis® preclinical software solution to support the collection, management and maintenance of the reproductive, perinatal and developmental National Toxicology Program studies. These studies are done predominantly at contractor laboratories at various sites throughout the United States.

13 Aug 2010

Major turning point in antiepileptic drug testing, development

New York University researchers revealed that data from previously completed withdrawal to monotherapy studies for antiepileptic drugs provide a valid control for future studies, obviating the need for placebo/pseudo-placebo trials to demonstrate the efficacy of these drugs as monotherapy. Results of this study are now available online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

21 Jul 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

ACRO calls for sufficient resources for FDA to monitor foreign clinical trials

The Association of Clinical Research Organizations, which represents the global CRO industry, today released the following statement regarding a report from the Office of the Inspector General (OIG) of the Department of Health and Human Services (HHS) titled Challenges to FDA's Ability to Monitor and Inspect Foreign Clinical Trials.